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Summary.-cx1-Foetoprotein (AFP) levels have been measured by radioimmuno-
assay in the serum of 153 male patients with gonadal and extragonadal germ cell
tumours. Thirty-five patients with pure seminoma, and 34 patients with teratoma
but without any postoperative evidence of residual or recurrent tumour, consistently
had normal serum AFP levels (< 25 ng/ml). Of 84 patients with active teratomas,
56 (67%) had serological evidence ofAFP production. Ten patients with histological
evidence of pure yolk sac (endodermal sinus) tumours all had raised levels. Tera-
tomas containing yolk sac elements may or may not be associated with raised serum
levels. Trophoblastic (choriocarcinomatous) elements in a teratoma were not
normally associated with high values. Fourteen patients with teratomas had
elevated levels in the absence of histologically detectable yolk sac elements. Serum
AFP levels often became elevated before clinical evidence of recurrence, so that AFP
can act as an effective marker of the course of the disease and its response to therapy
in many patients, but recurrent or progressive disease may be present in the absence
of raised levels.
ax-Foetoprotein (AFP), one ofthe main
serum proteins of early human and other
mammalian foetuses (Abelev, 1968; Gitlin,
1974), is produced mainly by the embryo-
nic yolk sac and foetal liver (Gitlin,
Perricelli and Gitlin, 1972). Serum levels
decline shortly after birth, and remain low
throughout adult life (Masseyeff et al.,
1974). However, raised levels have been
detected in the amniotic fluid in associa-
tion with open neural tube defects
(Adinolfi, Adinolfi and Lessof, 1975), in
the serum during pregnancy, and in some
patients with primary hepatocellular car-
cinomas, germ cell tumours, metastatic
tumours of the liver, and non-neoplastic
liver disease (Laurence and Neville, 1972;
Silver et al., 1974). Tumours of other
endodermally derived organs may, in rare
instances, be associated with elevated
levels (Akai and Kato, 1973; McIntire et
al., 1975), although in such patients
plasma carcinoembryonic antigen (CEA)
is a more reliable tumour index (Grigor
et al., 1975).
Raised serum AFP levels may occur in
association with testicular tumours con-
taining teratomatous elements, but not
with seminomas or choriocarcinomas
(Abelev, 1968, 1974) and teratomas with
raised levels are said to carry a poorer
prognosis (N0rgaard-Pedersen, Albrech-
tsen and Teilum, 1975). The reasons for
this are unclear, but could be due to the
presence of a specific population of cells in
suchteratomas. Yolk sactumours inman
and animals have been shownto contain or
produce AFP (Ballas, 1972; Engelhardt,
Poltoranina and Yazova, 1973; Hooghe
and Zeicher, 1974; Teilum, Albrechtsen
and N0rgaard-Pederson, 1974, 1975), and
isolated reports of high serum AFP levels
with testicular tumours containing yolk
sac (endodermal sinus) elements or
polyembryoma have appeared (Abelev,
1974; Bourgeaux et al., 1971; TsuchidaALPHA-FOETOPROTEIN IN MALE GERM CELL TUMOURS
et al., 1973; Teilum et al., 1974, 1975).
The purposes of this paper were to
review a large series of patients with
malignant testicular and germ cell tum-
ours, and ascertain the clinical role of
serum AFP assays, and their relationship
to a comprehensive histopathological clas-
sification of these tumours.
MATERIALS AND METHODS
Patients.-The 153 patients of this study
were referred to the Royal Marsden Hospital
(RMH) Surrey and London for treatment of
malignant germ cell tumours initially diag-
nosed at other hospitals. All but 4 of these
patients had primary testicular tumours: one
patient had a primary mediastinal seminoma,
one had an abdominal yolk sac tumour, one
hadwidespreadteratoma withunknownsite of
origin, and one had a primary retroperitoneal
teratoma. The age at diagnosis ranged from
4 months to 79 years, with the peak incidence
in the third and fourth decades (Fig. 1).
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the tumours were classified- histologically
according to the British Testicular Tumour
Panel and Registry (Pugh, 1976) modified
slightly in order to examine the signifieance
of extraembryonic elements. Tumours with
the morphological features of endodermal
sinus tumours (Teilum, 1959) or yolk sac
tumours as defined by Teilum (1971, 1976)
were classified as yolk sac tumours. When
teratomas contained trophoblastic cells, the
non-trophoblastic elements were alsorecorded
for the sake of morphological and fuiictional
correlation.
Serum samples.-Ten ml of venous blood
was collected and the serum was separated by
centrifugation within 3 h and stored at
- 7000. Only 3 preorchidectomy serum
samples were available for study, because of
the referral system employed, but a sample
was taken when the patient first attended
RMH, before commencement ofpostoperative
therapy, and at each subsequent follow-up
visit.
cx1-Foetoprotein assay.-Serum AFP was
measured by radioimmunoassay. Anti-AFP
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FIG. 1.-Age at diagnosis and histological classification of 153 patients with testicular and extra-
gonadal germ cell tumours.
Histological material.-One hundred and
thirty-seven patients had an orchidectomy or
tumour biopsy before being referred to RMH.
All available histological material from these
tumours was reviewed. One patient had a
second orchidectomy at RMH, and 15 had
their original orchidectomy at RMH. All
antibody was raised in rabbits, and the free
and bound fractions were separated by
precipitation with ammonium sulphate or
polyethylene glycol. The sensitivity of this
method is 2 ng AFP per ml of undiluted
serum. Serum samples from 32 adult males
(aged between 20 and 40 years), with -no
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evidence of hepatic and malignant disease,
had AFP levels between 2 and 16 ng/ml
(mean 4-6 : 2-6 ng/ml). Values in excess of
25 ng/ml were considered in this study to be
elevated, and values between 16 and 25 ng/ml
were equivocal but not definitely raised.
RESULTS
Serum AFP levels as afunction of type and
activity of the tumour
The incidence of raised serum AFP
levels as a function of the different
histological types of tumour, and whether
disease is active or non-active, is illus-
trated in Table I. No patient with a pure
seminoma gave a raised value: of those
with active teratomas, alone or in com-
bination with a seminoma, 56/84 (67%o)
were associated with high serum AFP
levels, ranging from 28 to 88,000 ng/ml.
Four patients with teratomas had a raised
level in the first postoperative sample
only: normal values were detected there-
after, and no residual or recurrent disease
was discovered after a follow-up period
of between 12 and 21 months, indicating
that an elevated result shortly after sur-
gery does not necessarily signify the pres-
ence of residual disease, but suggests that
preoperative values were high and had
not had time to fall into the normal range.
An elevated serum AFP persisted for up
to 5 weeks in one patient.
Histological sub-types and AFP serum
levels
After extensive histological assessment,
29 of the 84 active teratomas were found
which could be classified as belonging to a
single histological sub-type (Table II).
It may be seen that in our series, pure yolk
sac tumours were always associated with
raised levels, while trophoblastic tumours
TABLE 1.-Serum AFP in 153 patients with Germ Cell
Tumours, According to Main Histological Classes and
Clinical Activity ofthe Tumours
Number of patients
Activity with serum AFP
Total of , A
Pathology patients disease* Normal Raisedt
Seminoma 35 Active 16 0
Non-active 19 0
Seminoma
+
Teratoma
Teratoma
24 Active
Non-active
94 Active
Non-active
8
7
20
26
9
0
47
1
* Patients with
" non-active
" disease are clinically free of residual or recurrent tumouir at the time of
serum sampling, and who remain clinically disease free for several months at subsequeint follow-uip.
Patients with " active " disease have clinically detectable tumour present at the time of sampling, or
develop overt recurrent disease during the follow-up period.
t > 25 ng/ml.
TABLE II.-Relationship of Specific Histological Features to Serum Levels of AFP in 29
Patients Who had Active Teratoma of a Single Histological Type
Teratomas consisting entirely of
Serum
AFP
Raised*
Normal
* > 25 ng/ml.
Malignant Malignant
Teratoma teratoma teratoma
differentiated initermediate undifferentiated
0
2
2
5
7
Malignant
Yolk sac teiratoma
tumour trophoblastic
10 0
0 2
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were not. Pure teratomas without extra-
embryonic elements, irrespective of their
differentiation, may be associated with
high levels (Table II). Many tumours,
however, contained admixtures of cell
types: this protean cellular composition
is reflected in Fig. 2, which shows serum
AFP levels of the various tumour types.
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FiG. 2. Serum level of AFP and histological
appearancea of the tumours in 84 patients
with active (lisease, excluding pure semi-
nomas.
The partial presence of yolk sac elements
is particularly, but not necessarily, associ-
ated with raised levels.
Serum AFP in follow-up studie8 and
therapeutic nmonitoring
All 153 patients had serum AFP
measured, and each patient had between
1 and 35 (mean 9) different samples
assayed over a period of up to 43 months
(mean 13 months). In most cases, the
course of the disease was followed by
sequential AFP estimations.
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Thirty-three patients had elevated
AFP in their first serum sample, and all
had persistently elevated levels for at
least one month postoperatively. All had
residual tumour present, and all have
subsequently died, except for 1 infant
(Fig. 3) who responded well to further
treatment.
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FIG. 3. Serum AFP levels in an infant who
had a left orchidectomy (Ox) for a pure yolk
sac tumour at the age of 31 moinths. His
AFP level was high postoperatively, in
spite of negative clinical examination, chest
X-ray (CXR), lymphogram (LG) and intra-
venous pyelogram (IVP); fell almost to
normal, and increased again to 40,000ng/ml,
although LG remained negative. Examin-
ation under anaesthesia (EUA) revealed a
left loin recurrence, which largely regressed
with chemotherapy using vincristine (V),
actinomycin D (A), cyclophosphamide (C)
and adriamycin (AD), and this was accom-
panied by a fall in serum AFP. At sub-
sequent laparotomy, residual tumour in the
left renal hilarlymph node, and the adjacent
adherent kidney, were removed: no other
intra-abdominal metastases were detected.
Serum AFP fell to normal after the laparo-
tomy and further AD therapy, and he
remains tumour-free and in good health.
Adjuvant chemotherapy and radio-
therapy in addition to surgical removal of
tumour usually resulted in a fall in AFP
levels (Figs. 3 and 4), but this was not
always accompanied by clinical regression
of the disease. Twenty-two patients had
falling AFP levels over a period when
therapy caused a reduction in tumour
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mass as judged clinically: however, 19
patients had evidence of progressive
*disease at a time when serum AFP was
falling, and at least 11 of these patients
had normal AFP levels at death (Fig. 4).
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FIG. 4. Serum AFP levels in a male patient
aet. 31, presenting with a right testicular
tumour and left iliac nodes, left supra-
clavicular node, lung and liver metastases.
Chemotherapy withvinblastine (V), actino-
mycin D (A) and methotrexate (M) caused
tumour regression, and a fallin serum AFP,
but normal values were not reached even
after orchidectomy (Ox), which revealed a
pure yolk sac tumour. Serum values rose to
3300 ng/ml, but following chemotherapy
and radiotherapy with additional actino-
mycin D (Act.D) he went into complete
clinical remission, including regression of
paraaortic and right eye metastases. A
subsequent rise in serum AFP preceded,
by several months, clinical evidence of
recurrent tumour when a liver scan
showed hepatic involvement. Chemo-
therapy again resulted in a fall in AFP
level to normal, but his metastatic disease
progressed, causing his death. Autopsy
showed widespread undifferentiated tera-
toma, with no evidence of yolk sac tumour.
Many patients responded to therapy
and went into complete clinical remission,
but subsequently relapsed and their serum
AFP increased. Three patients had a
clinical relapse detected at the same time
as AFP increased. Nine patients in
clinical remission developed an elevated
serum AFP prior to evidence of overt
clinical metastases (lead time 4 to 36
weeks, mean 15 weeks): however, 6
patients developed clinically overt recur-
rences before serum AFP levels rose above
normal (lag time 8 to 43 weeks, mean 23
weeks). Two patients who had clinical
recurrence before raised AFP levels, with
a lag time of more than 40 weeks, had
known seminomas with metastases. One
of these had an intrathoracic recurrence
biopsied, revealing a malignant teratoma
intermediate with yolk sac elements: the
other patient died of extensive metastatic
disease, but an autopsy was not per-
formed.
DISCUSSION
In our series of 153 patients with germ
cell tumours, we have shown that 67% of
84 patients with active teratomas had
raised serum AFP (> 25 ng/ml), but
patients with pure seminomas or pure
trophoblastic tumours (choriocarcinomas)
had normal serum levels. Pure yolk sac
tumours are always associated with raised
levels (Table II) but some teratomas
containing yolk sac elements did not cause
an increased serum AFP, and some
teratomas containing no recognizable yolk
sac elements were found to produce AFP.
These results suggestthat there is a strong,
but not absolute, association between
yolk sac tumour and AFP production:
however, interpretation of these data
requires caution. Because of the poly-
morphic appearance of germ cell tumours,
yolk sac elements may be present but not
identified, due to incomplete histological
sampling. Moreover, if yolk sac tumours
are seen to be part of an orchidectomy
specimen, recurrent tumour may contain
otherteratomatouselementsintheabsence
ofyolk sac tumour. Tsuchida et al. (1975)
have examined germ cell tumours associ-
ated with high serum AFP, and have re-
evaluated the histological features of
AFP-producing tumours, most of which
were reclassified as yolk sac tumours.
However, these authors did not re-
evaluate those tumours which did not
produce AFP, and in fact, although there
are many reports of yolk sac tumours
producing AFP, most authors do not state
how many yolk sac tumours are not
associated with AFP production.
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Teilum and his associates (N0rgaard-
Pedersen et al., 1975; Teilum et al., 1974,
1975) have demonstrated AFP in yolk sac
tumours by immunofluorescence, using
cryostat-sectioned material, or paraffin-
wax-embedded tissue prepared by the
Sainte-Marie method. However, Dr
Heyderman (personal communication) of
our group has, to date, failed to demon-
strate AFP specifically in formalin-fixed,
paraffin-embedded tissue using antibody
labelled with horse-radish peroxidase:
however, success with this approach will
be needed, if we are to determine which
cells are responsible for AFP production
in those tumours where there is no classical
histological evidence of yolk sac elements.
It is well known that germ cell
tumours containing trophoblastic elements
are often associated with high serum and/
or urinary HCG (human chorionic gonado-
trophin) levels. However, Cochran et al.
(1975) have demonstrated that raised
serum levels of the f-subunit of HCG
(HCG-,8) have been detected in 12/50
patients with testicular tumours con-
taining no histological evidence oftropho-
blastic tissue. Braunstein et al. (1973a)
have also demonstrated HCG-,/ in many
non-trophoblastic tumours. By analogy,
there is no reason to conclude that AFP-
producing testicular teratomas always
contain yolk sac elements, and if we
regard AFP and inappropriate hormones
as being similar, it must be remembered
that morphological and functional dif-
ferentiation need not always be associated.
Serum AFP measurements have a
valuable role to play in the follow-up of
patients with germ cell tumours. If
postoperative values fail to return to
normal after approximately one month,
residual tumour is present. Once a
patient is in complete clinical remission, a
recurrence is often preceded by a rise in
AFP levels, as we have shown in 9 patients
with a mean lead time of 15 weeks. How-
ever, tumour recurrence may be apparent
clinically before serum levels rise, or
serum AFP may increase simultaneously
with clinical evidence of metastatic dis-
ease. Tumours which are originally AFP-
producing may recur without an associated
elevation in serum levels, but tumours
which initially show no evidence of AFP
secretion may be accompanied by high
serum levels when recurrence supervenes.
In our series, a confirmed elevated serum
level ofAFP always indicated the presence
of active teratoma, and rising AFP levels
only occurred in patients with progressive
disease, whereas a falling AFP level may
indicate a good response to therapy but
may also accompany progressive disease,
and a normal serum AFP can occur in
patients with active tumour. Braunstein
et al. (1973b) and Perlin et al. (1976) have
shown that simultaneous monitoring of
serum AFP and HCG-,/ gives a more
reliable indication oftumour activity than
the measurement of either alone. In
many cases, the levels of these 2 markers
fluctuate independently ofeach other, as if
different cells were responsible for their
production, and had different respon-
siveness to chemotherapy.
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